Bacterial Infectious Diseases Therapeutics Market Size, Share, Industry, Forecast and outlook (2026-2035)

Bacterial Infectious Diseases Therapeutics Market Size

Bacterial Infectious Diseases Therapeutics Market was valued at USD 103.89 billion in 2025. It is forecasted to reach USD 228.48 billion by 2035, growing at a CAGR of 8.2% during the forecast period (2026-2035). 

Bacterial infectious diseases are infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including rod-shaped (bacilli), spherical (cocci), or helical (spirilla). Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by various signs and symptoms including bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.

As per DataM Intelligence, Bacterial Infectious Diseases Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Bacterial Infectious Diseases Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Bacterial Infectious Diseases Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Bacterial Infectious Diseases Therapeutics Market is projected to continue its presence globally from 2026 to 2035.

Bacterial Infectious Diseases Therapeutics Market Key Takeaways

• Market expansion: The bacterial infectious diseases therapeutics market reached USD 103.89 billion in 2025 and is projected to reach approximately USD 228.48 billion by 2035 at an 8.2% CAGR.
• Antibiotic resistance is a major commercial driver: The source identifies more than 2.8 million antibiotic-resistant infections annually in the United States and more than 35,000 related deaths, highlighting the need for new treatment options.
• Beta-lactam remains strategically important: Beta-lactams hold the largest share among therapeutics because of their broad clinical use and established penetration across penicillins, cephalosporins, carbapenems, and monobactams.
• North America leads current market demand: The region held the largest market share in 2021, supported by substantial therapeutic use, disease burden, pharmaceutical activity, and product approvals.
• Asia-Pacific provides the strongest growth opportunity: Rising healthcare investment, an expanding older population, greater awareness, increasing purchasing power, and domestic pharmaceutical capabilities support the region's faster growth trajectory.
• Retail pharmacies are commercially significant: Retail pharmacies are projected to experience high growth because of broad availability of antibacterial therapeutics and the expanding retail distribution network.
• Pipeline quality matters alongside pipeline volume: The source identifies 32 antibiotics in clinical development against WHO priority pathogens, but only six were considered innovative, underscoring the importance of differentiated antibacterial mechanisms and resistance-focused development.

Bacterial Infectious Diseases Therapeutics Market Scope

   For more insights Request Free Sample

Bacterial Infectious Diseases Therapeutics Market Dynamics

Growing Older Population is Driving the Growth of the Market

The demand for bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at a high risk of developing bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.

According to the United Nations (UN) report, the older population of age-group 65 years or above was 727 million worldwide in 2020. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has a higher older population in comparison to Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.

Increasing Antibacterial Resistance is Expected to Boost the Development of Therapeutics over the Forecast Period.

There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)’s new Global Antimicrobial Surveillance System (GLASS), antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 86% of new TB cases in  30 high  TB burden countries in 2020.

Several factors such as misuse and overuse of antibacterial, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in healthcare facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is a rising spread of multi- and pan-resistant bacteria infections not being treatable by using the existing antibacterial worldwide. The increasing antibacterial resistance has resulted in the rising development of therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of several therapeutics being developed. Several companies are developing therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterial. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in the pipeline, only six were classified as innovative.

Rising Organizations & Institutes Initiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth

Several organizations & institutes have raised initiatives for overcoming antibacterial resistance. For instance, The India government has launched a “National Programme on AMR Containment during the 12th five-year plan, which is coordinated by NCDC. This phased manner included 35 state medical college labs and 26 states/UT. World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.

The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.

Bacterial Infectious Diseases Therapeutics Market Segment Analysis

Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market

By therapeutics, the market is classified as beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. The Beta-lactam segment is anticipated to hold the largest share as it is the most prescribed antibacterial for the prevention & treatment of bacterial infection. The beta-lactam acts by inhibiting cell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. β-Lactam antibiotics are effective against a broad range of clinical indications. Penicillin’s, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterial with the highest market penetration.

There is increasing research and development activities for beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).

By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies are segmented to have the highest market growth due to the high availability of therapeutics for the treatment of bacterial infectious diseases in the retail pharmacies & drug stores. There is an increase in the number of retail stores across the globe. According to the cross-sectional survey, approximately 93.5% of antibiotics including amoxicillin and trimethoprim-sulfamethoxazole were prescribed by the majority of the registered drug shops.

Bacterial Infectious Diseases Therapeutics Market Geographical Share

North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market

North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2021 owing to the increasing prevalence of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 7,860 in the United States in 2021. The total number of incidence cases of salmonella and Lyme disease was 58,371 and 34,945 respectively in the United States in 2019. There is a growing prevalence of antibacterial resistant infections. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by antibiotic-resistant infections 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.

The United States accounts for the highest market share due to the higher usage of therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval & launch of therapeutics for the treatment of bacterial infectious diseases. For instance, on 4th June 2020, the United States Food and Drug Administration approved Recarbrio. The Recarbrio is to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older. The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of the population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities & infrastructure shall have a positive impact on the market.

There is increasing research and development activities for the development of therapeutics for the treatment of bacterial infectious diseases. There is a presence of several market players developing therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.

Bacterial Infectious Diseases Therapeutics Market Major players and Competitive Landscape

The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of a large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In July 2019, Nosopharm had entered into the collaboration with Evotec SE for advancing the NOSO-502, a novel antibiotic class against Enterobacteriace infections to the clinical stage of development and develop a second-generation Odilorhabdin for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)

Product Launch & Approvals:

In July 2019, Merck & Co. had received approval from the United States Food and Drug Administration (FDA) for the Recarbrio (imipenem, cilastatin, and relebactam) injection, 1.25 grams, a new combination antibacterial. Recarbrio is recommended for the patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumonia, and Pseudomonas aeruginosa.

In July 2019, Merck & Co. had received the approval for Zerbaxa (ceftolozane and tazobactam) from the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Allergan plc had received the approval to expand the use of Avycaz (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms including the Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenza in patients 18 years of age or older.

On 19th August 2019, The United States Food and Drug Administration approved Xenleta to treat adults with community-acquired bacterial pneumonia. This new drug provides a better option for treating patients with community-acquired bacterial pneumonia.

Acquisition:

In February 2020, Grifols had acquired the Aradigm, an antibiotic developer.

On 11th October 2021, Sandoz completed the acquisition of GSK’s cephalosporin business, confirming Sandoz's commitment to the antibiotics business.

Regulatory and Antimicrobial Resistance Considerations

Antibacterial resistance has a direct impact on pharmaceutical development, prescribing practices, healthcare expenditure, and product access. The source identifies several underlying causes, including inappropriate antibiotic use, insufficient sanitation, limited infection prevention, inadequate access to diagnostics and quality medicines, and gaps in public awareness.

Regulatory initiatives such as the U.S. GAIN Act demonstrate the importance of policy support for antibacterial development. For companies, regulatory incentives can influence the commercial feasibility of programs targeting priority pathogens, particularly when clinical development requirements are substantial and patient populations may be relatively focused.

For procurement teams and healthcare providers, antimicrobial stewardship is equally important. Expanding access to antibacterial therapies must be balanced with appropriate prescribing and responsible use to protect therapeutic effectiveness.

How the Market Develops Across the Value Chain

The opportunity extends across the pharmaceutical value chain rather than being concentrated among drug manufacturers alone. Diagnostic companies can support earlier identification of bacterial infections and resistance patterns. Pharmaceutical developers can address unmet treatment needs through new molecules and combinations. Distribution companies can expand access to approved therapies, while healthcare providers remain central to prescribing and treatment decisions.

The strongest strategic positions are likely to come from organizations that understand both sides of the market: the clinical need for effective antibacterial treatment and the operational requirement for responsible antibiotic utilization.

Report Benefits

For Manufacturers

The report supports portfolio planning by identifying major therapeutic categories, regional demand patterns, distribution channels, competitive activity, and development priorities associated with bacterial infectious diseases therapeutics.

For Investors

Investors can use the market trajectory, resistance-driven demand, regional growth outlook, company activity, and development trends to evaluate potential investment timing and areas of pharmaceutical opportunity.

For Suppliers and Technology Companies

Suppliers can assess opportunities across pharmaceutical distribution, diagnostics, research support, manufacturing, and healthcare infrastructure connected with bacterial infection management.

For Procurement Teams

Procurement professionals can use the analysis to understand therapeutic availability, distribution channels, regional demand, and the factors influencing antibacterial product adoption.

For Strategy and Corporate Development Teams

Strategy teams can evaluate partnerships, acquisitions, product expansion, regional entry opportunities, and competitive positioning within a fragmented antibacterial therapeutics market.

Target Audience

• Pharmaceutical and biotechnology companies
• Antibiotic and antibacterial drug developers
• Healthcare providers and hospital systems
• Pharmaceutical distributors and retail pharmacy operators
• Diagnostics and infectious disease testing companies
• Investors and private equity firms
• Corporate strategy and business development teams
• Procurement and sourcing professionals
• Government healthcare agencies
• Antimicrobial resistance program managers
• Research institutions and clinical development organizations

Conclusion

The bacterial infectious diseases therapeutics market combines a large existing treatment base with a growing need for more effective responses to resistant bacterial pathogens. From the source value of USD 75.8 billion in 2021, the market is recalculated at USD 103.89 billion in 2025 and approximately USD 228.48 billion by 2035 using the reported 8.2% CAGR.

The commercial case is supported by population aging, persistent bacterial disease burdens, antimicrobial resistance, healthcare infrastructure investment, and continuing pharmaceutical development. North America provides the strongest established market position, while Asia-Pacific offers a particularly important growth avenue as healthcare access, population aging, and pharmaceutical capabilities expand.

For pharmaceutical companies, the central strategic question is increasingly how to develop and commercialize therapies that remain clinically useful as resistance patterns change. Beta-lactams continue to provide a substantial commercial foundation, but development activity around resistant pathogens, novel antibacterial classes, combination therapies, and targeted indications will influence future competitive positioning.

Companies with differentiated pipelines, strong regulatory capabilities, effective partnerships, and access to high-growth regional markets are positioned to capture a greater share of the opportunity. For investors, procurement teams, and healthcare decision-makers, tracking therapeutic innovation, resistance trends, regulatory policy, and regional infrastructure now provides a stronger basis for evaluating the market's direction through 2035.